Article
Uroplasty, Inc. has received an approvable letter from the FDA relating to its pre-market approval application for Macroplastique implants for the treatment of female stress urinary incontinence.
Uroplasty, Inc. has received an approvable letter from the FDA relating to its pre-market approval application for Macroplastique implants for the treatment of female stress urinary incontinence.
The product is a soft tissue, injectable bulking agent for use in a minimally invasive, outpatient procedure. When a physician injects Macroplastique into the tissues surrounding the urethra, the increased bulk allows the urethra to close more effectively and prevents urine from leaking, the company said.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.